Overview

A LM-302 Combined With Toripalimab Phase II Study

Status:
Recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

A Phase II, Open-Label, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of LM-302 Combined With Toripalimab in CLDN18.2 Positive Patients advanced gastro-Intestinal Cancer

Phase:

Phase 2

Details

Lead Sponsor:

LaNova Medicines Zhejiang Co., Ltd.